FLNA
Filana Therapeutics, Inc.
Price Chart
Latest Quote
$1.24
+0.02 (+1.64%)
Current Price
| Previous Close | $1.22 |
| Open | $1.22 |
| Day High | $1.26 |
| Day Low | $1.22 |
| Volume | 355,597 |
Stock Information
| Shares Outstanding | 48.31M |
| Cash Equivalents | $86.57M |
| Net Income | $-77.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $59.90M |
| EPS (TTM) | $-1.61 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-26.67M |
| Income | $-77.90M |
| Book/sh | $1.41 |
| Cash/sh | $1.79 |
| Employees | 17 |
Financial Ratios
| Quick Ratio | 2.16 |
| Current Ratio | 2.19 |
Returns & Margins
| ROA | -24.91% |
| ROE | -79.59% |
Ownership
| Insider Ownership | 11.02% |
| Institutional Ownership | 28.72% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 1.62 |
| P/B | 0.88 |
Analyst Data
| Recommendation | none |
| Target Price | $6.50 |
Technical Indicators
| SMA20 | $1.36 |
| SMA50 | $1.42 |
| SMA200 | $2.29 |
| RSI | 30.16 |
| ATR | 0.0850 |
| Shares Float | 47.32M |
| Short Float | 14.55% |
| Short Ratio | 15.51 |
| Volatility | -0.78 |
| Rel Volume | 0.93 |
Performance History
| Week | -0.80% |
| Month | -0.80% |
| Quarter | -30.73% |
| 6 Months | -56.49% |
| YTD | -40.67% |
| Year | -40.10% |
| 3 Years | -95.10% |
| 5 Years | -98.36% |
| 10 Years | -91.44% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.24 | 357,100 |
| 2026-06-18 | $1.22 | 464,600 |
| 2026-06-17 | $1.21 | 308,700 |
| 2026-06-16 | $1.22 | 442,100 |
| 2026-06-15 | $1.21 | 472,900 |
| 2026-06-12 | $1.25 | 193,000 |
| 2026-06-11 | $1.31 | 262,700 |
| 2026-06-10 | $1.32 | 235,800 |
| 2026-06-09 | $1.42 | 359,100 |
| 2026-06-08 | $1.43 | 344,900 |
| 2026-06-05 | $1.32 | 326,100 |
| 2026-06-04 | $1.40 | 199,700 |
| 2026-06-03 | $1.36 | 292,900 |
| 2026-06-02 | $1.44 | 378,900 |
| 2026-06-01 | $1.49 | 579,100 |
| 2026-05-29 | $1.54 | 509,400 |
| 2026-05-28 | $1.55 | 399,600 |
| 2026-05-27 | $1.50 | 625,400 |
| 2026-05-26 | $1.41 | 701,200 |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $96,126,000 | $142,279,000 | $107,333,000 | $81,482,000 |
| Other Income Expense | $533,000 | $109,427,000 | $2,283,000 | $2,459,000 |
| Other Non Operating Income Expenses | $533,000 | $1,244,000 | $2,283,000 | $2,459,000 |
| Net Non Operating Interest Income Expense | $4,620,000 | $8,510,000 | $7,833,000 | $2,777,000 |
| Operating Expense | $96,126,000 | $142,279,000 | $107,333,000 | $81,482,000 |
| Other Operating Expenses | $736,000 | $833,000 | $1,376,000 | $1,462,000 |
| General And Administrative Expense | $68,800,000 | $71,809,000 | $16,534,000 | $11,988,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Net Interest Income | $4,620,000 | $8,510,000 | $7,833,000 | $2,777,000 |
| Interest Income | $4,620,000 | $8,510,000 | $7,833,000 | $2,777,000 |
| Normalized Income | $-90,973,000 | $-132,525,000 | $-97,217,000 | $-76,246,000 |
| Net Income From Continuing And Discontinued Operation | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Total Operating Income As Reported | $-95,390,000 | $-141,446,000 | $-105,957,000 | $-80,020,000 |
| Average Dilution Earnings | $0 | $-43,793,000 | $0 | $0 |
| Net Income Common Stockholders | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Net Income | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Net Income Including Noncontrolling Interests | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Net Income Continuous Operations | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Pretax Income | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Interest Income Non Operating | $4,620,000 | $8,510,000 | $7,833,000 | $2,777,000 |
| Operating Income | $-96,126,000 | $-142,279,000 | $-107,333,000 | $-81,482,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.88 | $-1.46 | $-2.32 | $-1.90 |
| Basic EPS | $-1.88 | $-0.53 | $-2.32 | $-1.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-95,190,000 | $-249,330,000 | $-105,803,000 | $-80,181,000 |
| Reconciled Depreciation | $936,000 | $1,132,000 | $1,530,000 | $1,301,000 |
| EBITDA (Bullshit earnings) | $-95,190,000 | $-141,147,000 | $-105,803,000 | $-80,181,000 |
| EBIT | $-96,126,000 | $-142,279,000 | $-107,333,000 | $-81,482,000 |
| Diluted Average Shares | $48,297,000 | $46,604,000 | $41,932,000 | $40,202,000 |
| Basic Average Shares | $48,297,000 | $46,329,000 | $41,932,000 | $40,202,000 |
| Diluted NI Availto Com Stockholders | $-90,973,000 | $-68,135,000 | $-97,217,000 | $-76,246,000 |
| Research And Development | $26,590,000 | $69,637,000 | $89,423,000 | $68,032,000 |
| Selling General And Administration | $68,800,000 | $71,809,000 | $16,534,000 | $11,988,000 |
| Other Gand A | $68,800,000 | $71,809,000 | $16,534,000 | $11,988,000 |
| Total Unusual Items | - | $108,183,000 | - | $0 |
| Total Unusual Items Excluding Goodwill | - | $108,183,000 | - | $0 |
| Gain On Sale Of Security | - | $108,183,000 | - | - |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $74,403,000 | $145,704,000 | $137,292,000 | $226,917,000 |
| Total Assets | $118,355,000 | $157,533,000 | $151,663,000 | $234,834,000 |
| Total Non Current Assets | $20,646,000 | $21,001,000 | $22,030,000 | $23,608,000 |
| Current Assets | $97,709,000 | $136,532,000 | $129,633,000 | $211,226,000 |
| Other Current Assets | $64,000 | $38,000 | $287,000 | $160,000 |
| Prepaid Assets | $2,023,000 | $6,973,000 | $7,248,000 | $10,051,000 |
| Receivables | $120,000 | $947,000 | $962,000 | $0 |
| Accrued Interest Receivable | $120,000 | $947,000 | $962,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $95,502,000 | $128,574,000 | $121,136,000 | $201,015,000 |
| Cash And Cash Equivalents | $95,502,000 | $128,574,000 | $121,136,000 | $201,015,000 |
| Goodwill And Other Intangible Assets | - | $37,000 | $176,000 | $622,000 |
| Other Intangible Assets | - | $37,000 | $176,000 | $622,000 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | $0 | $139,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $35,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $104,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $43,952,000 | $11,829,000 | $14,195,000 | $7,295,000 |
| Total Non Current Liabilities Net Minority Interest | $118,000 | $79,000 | $0 | $232,000 |
| Other Non Current Liabilities | $118,000 | $79,000 | - | $197,000 |
| Current Liabilities | $43,834,000 | $11,750,000 | $14,195,000 | $7,063,000 |
| Other Current Liabilities | $198,000 | $299,000 | $385,000 | $492,000 |
| Payables And Accrued Expenses | $42,011,000 | $10,094,000 | $13,610,000 | $6,297,000 |
| Payables | $41,647,000 | $7,654,000 | $10,573,000 | $4,017,000 |
| Accounts Payable | $41,647,000 | $7,654,000 | $10,573,000 | $4,017,000 |
| Equity | ||||
| Common Stock Equity | $74,403,000 | $145,704,000 | $137,468,000 | $227,539,000 |
| Total Equity Gross Minority Interest | $74,403,000 | $145,704,000 | $137,468,000 | $227,539,000 |
| Stockholders Equity | $74,403,000 | $145,704,000 | $137,468,000 | $227,539,000 |
| Retained Earnings | $-496,084,000 | $-405,111,000 | $-380,769,000 | $-283,552,000 |
| Other | ||||
| Ordinary Shares Number | $48,307,896 | $48,203,179 | $42,236,919 | $41,735,557 |
| Share Issued | $48,307,896 | $48,203,179 | $42,236,919 | $41,735,557 |
| Tangible Book Value | $74,403,000 | $145,704,000 | $137,292,000 | $226,917,000 |
| Invested Capital | $74,403,000 | $145,704,000 | $137,468,000 | $227,539,000 |
| Working Capital | $53,875,000 | $124,782,000 | $115,438,000 | $204,163,000 |
| Total Capitalization | $74,403,000 | $145,704,000 | $137,468,000 | $227,539,000 |
| Additional Paid In Capital | $570,439,000 | $550,767,000 | $518,195,000 | $511,049,000 |
| Capital Stock | $48,000 | $48,000 | $42,000 | $42,000 |
| Common Stock | $48,000 | $48,000 | $42,000 | $42,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,625,000 | $1,357,000 | $200,000 | $170,000 |
| Current Accrued Expenses | $364,000 | $2,440,000 | $3,037,000 | $2,280,000 |
| Net PPE | $20,646,000 | $21,001,000 | $21,854,000 | $22,986,000 |
| Accumulated Depreciation | $-4,139,000 | $-3,236,000 | $-2,284,000 | $-1,200,000 |
| Gross PPE | $24,785,000 | $24,237,000 | $24,138,000 | $24,186,000 |
| Leases | $3,468,000 | $3,062,000 | $3,062,000 | $3,016,000 |
| Construction In Progress | $25,000 | $55,000 | $0 | $13,000 |
| Other Properties | $687,000 | $531,000 | $494,000 | $470,000 |
| Machinery Furniture Equipment | $891,000 | $875,000 | $868,000 | $851,000 |
| Buildings And Improvements | $15,980,000 | $15,980,000 | $15,980,000 | $16,102,000 |
| Land And Improvements | $3,734,000 | $3,734,000 | $3,734,000 | $3,734,000 |
| Properties | $0 | $0 | $0 | $0 |
| Capital Lease Obligations | - | - | $0 | $139,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $35,000 |
| Current Capital Lease Obligation | - | - | $0 | $104,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-32,833,000 | $-117,032,000 | $-82,439,000 | $-80,226,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-32,252,000 | $-116,929,000 | $-82,025,000 | $-77,514,000 |
| Cash Flow From Continuing Operating Activities | $-32,252,000 | $-116,929,000 | $-82,025,000 | $-77,514,000 |
| Operating Gains Losses | - | $-108,183,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-581,000 | $-103,000 | $-414,000 | $-2,712,000 |
| Investing Cash Flow | $-581,000 | $-103,000 | $-414,000 | $-2,712,000 |
| Cash Flow From Continuing Investing Activities | $-581,000 | $-103,000 | $-414,000 | $-2,712,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-239,000 | $124,470,000 | $2,560,000 | $47,804,000 |
| Cash Flow From Continuing Financing Activities | $-239,000 | $124,470,000 | $2,560,000 | $47,804,000 |
| Net Other Financing Charges | $-329,000 | - | - | - |
| Issuance Of Capital Stock | - | $0 | $0 | $47,329,000 |
| Net Common Stock Issuance | - | $0 | $0 | $47,329,000 |
| Common Stock Issuance | - | $0 | $0 | $47,329,000 |
| Other | ||||
| End Cash Position | $95,502,000 | $128,574,000 | $121,136,000 | $201,015,000 |
| Beginning Cash Position | $128,574,000 | $121,136,000 | $201,015,000 | $233,437,000 |
| Changes In Cash | $-33,072,000 | $7,438,000 | $-79,879,000 | $-32,422,000 |
| Proceeds From Stock Option Exercised | $90,000 | $124,470,000 | $2,560,000 | $475,000 |
| Net PPE Purchase And Sale | $-581,000 | $-103,000 | $-414,000 | $-2,712,000 |
| Purchase Of PPE | $-581,000 | $-103,000 | $-414,000 | $-2,712,000 |
| Change In Working Capital | $38,203,000 | $-1,827,000 | $9,076,000 | $-4,635,000 |
| Change In Other Working Capital | $268,000 | $1,157,000 | $13,000 | $-1,716,000 |
| Change In Other Current Liabilities | $-62,000 | $-7,000 | $-304,000 | $-136,000 |
| Change In Payables And Accrued Expense | $31,917,000 | $-3,516,000 | $7,653,000 | $-3,972,000 |
| Change In Accrued Expense | $-2,076,000 | $-597,000 | $757,000 | $-523,000 |
| Change In Payable | $33,993,000 | $-2,919,000 | $6,896,000 | $-3,449,000 |
| Change In Account Payable | $33,993,000 | $-2,919,000 | $6,896,000 | $-3,449,000 |
| Change In Prepaid Assets | $6,080,000 | $539,000 | $1,714,000 | $1,189,000 |
| Stock Based Compensation | $19,582,000 | $16,291,000 | $4,586,000 | $2,066,000 |
| Depreciation Amortization Depletion | $936,000 | $1,132,000 | $1,530,000 | $1,301,000 |
| Depreciation And Amortization | $936,000 | $1,132,000 | $1,530,000 | $1,301,000 |
| Amortization Cash Flow | $33,000 | $180,000 | $446,000 | $497,000 |
| Amortization Of Intangibles | $33,000 | $180,000 | $446,000 | $497,000 |
| Depreciation | $903,000 | $952,000 | $1,084,000 | $804,000 |
| Net Income From Continuing Operations | $-90,973,000 | $-24,342,000 | $-97,217,000 | $-76,246,000 |
| Gain Loss On Investment Securities | - | $-108,183,000 | - | - |
| Sale Of PPE | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-22